Welcome
Support Centre
21 March 2013 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Adjuvant Tamoxifen Treatment - offer more? To assess reliably the balance of benefits and risks of prolonging adjuvant tamoxifen treatment by 5 years for women with breast cancer
ISRCTN ISRCTN17222211
DOI 10.1186/ISRCTN17222211
ClinicalTrials.gov identifier NCT00003678
EudraCT number
Public title Adjuvant Tamoxifen Treatment - offer more? To assess reliably the balance of benefits and risks of prolonging adjuvant tamoxifen treatment by 5 years for women with breast cancer
Scientific title
Acronym aTTom
Serial number at source BR3009
Study hypothesis To assess reliably, the balance of benefits and risks of prolonging adjuvant tamoxifen treatment by 5 years, in women with early breast cancer
Lay summary http://cancerhelp.cancerresearchuk.org/trials/tamoxifen-for-early-stage-breast-cancer
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Breast cancer
Participants - inclusion criteria 1. Any woman who has had complete excision of breast carcinoma
2. Any primary treatment
3. At least 2 years of prior adjuvant tamoxifen treatment (5 recommended)
4. Clinically relapse free
5. No definite indications or contraindications for further tamoxifen treatment: uncertainty as to whether further tamoxifen treatment will be of benefit
6. Where possible, ER status should be known prior to randomisation
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/1994
Anticipated end date 01/08/2014
Status of trial Ongoing
Patient information material
Target number of participants 8000
Interventions Group A - No further treatment with tamoxifen
Group B - At least 5 years further treatment with tamoxifen
Primary outcome measure(s) To detect or refute reliably any overall survival benefit from extending the duration of therapy with adjuvant tamoxifen
Secondary outcome measure(s) Not provided at time of registration
Sources of funding 1. Cancer Research UK (UK)
2. Medical Research UK (UK)
Trial website
Publications
Contact name Mr  Martin J  Lee
  Address Birmingham Clinical Trials Unit
University of Birmingham
Park Grange, 1 Somerset Road
Edgbaston
  City/town Birmingham
  Zip/Postcode B15 2RR
  Country United Kingdom
  Email
Sponsor The University of Birmingham (UK)
  Address Edgbaston
  City/town Birmingham
  Zip/Postcode B15 2TT
  Country United Kingdom
  Email
Date applied 22/03/2001
Last edited 01/12/2011
Date ISRCTN assigned 22/03/2001
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2013 ISRCTN unless otherwise stated.